Hepatotoxicity of camptothecin derivatives in a primary culture system of rat hepatocytes

Journal of Chemotherapy

Volumn 12, Issue 4, 2000, Pages 345-351

  Fulco, R A ^a   Costa, C ^a   Germano, M P ^a   Torre, E A ^a   Viscomi, M G ^a   Salimbeni, V ^a   Maisano, R ^a   Giudice, A ^a   Costa, G ^a  

^a NONE   (Italy)

Author keywords

Camptothecin; Cell culture; Hepatotoxicity; Irinotecan; Topoisomerase I inhibitors; Topotecan; Toxicity

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; DNA TOPOISOMERASE INHIBITOR; IRINOTECAN; LACTATE DEHYDROGENASE; MITOCHONDRIAL DNA; TOPOTECAN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG CYTOTOXICITY; ENZYME ASSAY; ENZYME INHIBITION; LIVER CELL CULTURE; LIVER TOXICITY; MALE; NONHUMAN; RAT;

EID: 0033883625     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2000.12.4.345     Document Type: Article

References (28)

1. Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC 100880)
2. Topoisomerase I inhibitors topotecan and trinotecan
3. Antitumor effect of CPT- II, a new derivative of camptothecin against pleiotropic drug-resistant tumor in vitro and in vivo
4. Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice
5. Activity of CPT-11 (trinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units
6. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
7. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
8. No alteration in DNA topoisomerase I gene related to CPT-11 resistance in human lung cancer
9. Late phase II clinical study of irinotecan hydrochloride (CPT-11) in the treatment of malignant lymphoma and acute leukemia. The CPT-11 Research Group for Hematological Malignancies
10. Phan-nacokinetics of SN38 [7-ethyl-10-hydroxy-camptothecin], an active metabolite of irinotecan, after a single intravenous dosing of 14C-SN38 to rats
11. Rat serum carboxylesterase. Cloning, expression, regulation, and evidence of secretion from liver
12. In vitro activation of irinotecan to SN-38 by human liver and intestine
13. Preparation of isolated liver cells
14. Preparation of liver cells
15. Phase I phannacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
16. CPT-11 clinical experience in phase I studies
17. Clinical pharmacokinetics of topotecan
18. Phase I clinical and pharmacokinetic study of irinotecan
19. Influence of age on the pharmacokinetics of irinotecan (CPT- I 1) and its metabolite, SN-38 and SN-8 glucuronide (SN-38G) in patients with previously treated colorectal cancer
20. Correlation of in vitro and in vivo hepatotoxicity for five haloalkanes
21. Rapid calorimetric assay for cellular growth and survival. Application to proliferation and cytotoxicity assays
22. An in vitro approach to the study of target organ toxicity of drugs and chemicals
23. Differential requirement of DNA replication for the cytotoxicity of DNA topoisomerase I and 11 inhibitors in Chinese hamster DC3F cells
24. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies
25. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials
26. Population pharmacokinetics and pharmacodynamics of irinotecan (CPT-11) and active metabolite SN38 during phase I trials
27. Attachment and long term survival of adult rat hepatocytes in primary monolayer cultures: Comparison of different substrata and tissue culture media formulations